Transforming Growth Factor and Pre-Eclampsia: Perspectives for Novel Therapeutic ModalitiesParveen Jahan1*, Goske Deepthi2, Kamakshi Chaithri Ponnaluri2 and Komaravalli Prasanna Latha2
- *Corresponding Author:
- Parveen Jahan
Department of Zoology, MANUU
Hyderabad-32, Telangana State, India
E-mail: [email protected]
Received date: February 17, 2016 Accepted date: March 07, 2016 Published date: March 10, 2016
Citation: Jahan P, Deepthi G, Ponnaluri KC, Latha KP (2016) Transforming Growth Factor - B1 and Pre-Eclampsia: Perspectives for Novel Therapeutic Modalities. Immunother Open Acc 2:113. doi:10.4172/2471-9552.1000113
Copyright: © 2016 Jahan P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Breakdown in the immunoregulatory mechanism as well as dysregulated angiogenesis are critical contributors to the obstetric disorder, Pre-eclampsia [PE]. The pleiotropic cytokine, Transforming Growth Factor-β1 [TGF-β1], with its immunosuppressive and angiogenic functions appears to be a promising candidate for prospective therapies in PE, as gleaned from a survey of candidate gene association and biochemical investigations. The current article endows with a background and gives inkling for the plausible therapeutic strategies for PE employing TGF-β1, given the veracity that proper curative procedures are not yet existent for this disorder.